{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T09:47:14Z","timestamp":1793526434843,"version":"4.5.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,7,10]],"date-time":"2017-07-10T00:00:00Z","timestamp":1499644800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100010028","name":"University of Huddersfield","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100010028","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS PharmSciTech"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1208\/s12249-017-0841-y","type":"journal-article","created":{"date-parts":[[2017,7,10]],"date-time":"2017-07-10T16:47:47Z","timestamp":1499705267000},"page":"251-261","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Study of the Emitted Dose After Two Separate Inhalations at Different Inhalation Flow Rates and Volumes and an Assessment of Aerodynamic Characteristics of Indacaterol Onbrez Breezhaler\u00ae 150 and 300\u00a0\u03bcg"],"prefix":"10.1208","volume":"19","author":[{"given":"Mohamad","family":"Abadelah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry","family":"Chrystyn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Golshan","family":"Bagherisadeghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaballa","family":"Abdalla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hassan","family":"Larhrib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,7,10]]},"reference":[{"issue":"6","key":"841_CR1","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1183\/09031936.00166410","volume":"37","author":"BL Laube","year":"2011","unstructured":"Laube BL, Janssens HM, de Jongh FH, Devadason SG, Dhand R, Diot P, et al. What the pulmonary specialist should know about the new inhalation therapies. Eur Respir J. 2011;37(6):1308\u2013417.","journal-title":"Eur Respir J"},{"issue":"2","key":"841_CR2","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1089\/jam.1993.6.99","volume":"6","author":"A Clark","year":"1993","unstructured":"Clark A, Hollingworth A. The relationship between powder inhaler resistance and peak inspiratory conditions in healthy volunteers\u2014implications for in vitro testing. J Aerosol Med. 1993;6(2):99\u2013110.","journal-title":"J Aerosol Med."},{"issue":"2","key":"841_CR3","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1053\/rmed.2003.1351","volume":"97","author":"H Chrystyn","year":"2003","unstructured":"Chrystyn H. Is inhalation rate important for a dry powder inhaler? Using the In-Check Dial to identify these rates. Respir Med. 2003;97(2):181\u20137.","journal-title":"Respir Med"},{"issue":"3","key":"841_CR4","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.rmedc.2010.10.004","volume":"3","author":"J Haughney","year":"2010","unstructured":"Haughney J, Price D, Barnes NC, Virchow JC, Roche N, Chrystyn H. Choosing inhaler devices for people with asthma: current knowledge and outstanding research needs. Respir Med CME. 2010;3(3):125\u201331.","journal-title":"Respir Med CME"},{"issue":"1","key":"841_CR5","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0378-5173(97)00097-5","volume":"153","author":"A Boer De","year":"1997","unstructured":"De Boer A, Bolhuis G, Gjaltema D, Hagedoorn P. Inhalation characteristics and their effects on in vitro drug delivery from dry powder inhalers: part 3: the effect of flow increase rate (FIR) on the in vitro drug release from the Pulmicort 200 Turbuhaler. Int J Pharm. 1997;153(1):67\u201377.","journal-title":"Int J Pharm"},{"issue":"1","key":"841_CR6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2049-6958-10-1","volume":"10","author":"RW Dal Negro","year":"2015","unstructured":"Dal Negro RW. Dry powder inhalers and the right things to remember: a concept review. Multidisciplinary respiratory medicine. 2015;10(1):1.","journal-title":"Multidisciplinary respiratory medicine"},{"issue":"11","key":"841_CR7","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1016\/j.rmed.2007.06.008","volume":"101","author":"RA Al-Showair","year":"2007","unstructured":"Al-Showair RA, Tarsin WY, Assi KH, Pearson SB, Chrystyn H. Can all patients with COPD use the correct inhalation flow with all inhalers and does training help? Respir Med. 2007;101(11):2395\u2013401.","journal-title":"Respir Med"},{"key":"841_CR8","first-page":"353","volume":"6","author":"KR Chapman","year":"2011","unstructured":"Chapman KR, Fogarty CM, Peckitt C, Lassen C, Jadayel D, Dederichs J, et al. Delivery characteristics and patients\u2019 handling of two single-dose dry-powder inhalers used in COPD. Int J Chron Obstruct Pulmon Dis. 2011;6:353\u201363.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"2","key":"841_CR9","doi-asserted-by":"crossref","first-page":"208","DOI":"10.4104\/pcrj.2012.00010","volume":"21","author":"W Azouz","year":"2012","unstructured":"Azouz W, Chrystyn H. Clarifying the dilemmas about inhalation techniques for dry powder inhalers: integrating science with clinical practice. Prim Care Respir J. 2012;21(2):208\u201313.","journal-title":"Prim Care Respir J"},{"issue":"1","key":"841_CR10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12890-016-0169-5","volume":"16","author":"H Chrystyn","year":"2016","unstructured":"Chrystyn H, Price DB, Molimard M, Haughney J, Bosnic-Anticevich S, Lavorini F, et al. Comparison of serious inhaler technique errors made by device-na\u00efve patients using three different dry powder inhalers: a randomised, crossover, open-label study. BMC Pulmonary Medicine. 2016;16(1):1.","journal-title":"BMC Pulmonary Medicine"},{"issue":"1","key":"841_CR11","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s12890-015-0043-x","volume":"15","author":"W Azouz","year":"2015","unstructured":"Azouz W, Chetcuti P, Hosker H, Saralaya D, Chrystyn H. Inhalation characteristics of asthma patients, COPD patients and healthy volunteers with the Spiromax\u00ae and Turbuhaler\u00ae devices: a randomised, cross-over study. BMC Pulmonary Medicine. 2015;15(1):47.","journal-title":"BMC Pulmonary Medicine."},{"issue":"1","key":"841_CR12","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1089\/jamp.2013.1119","volume":"28","author":"W Azouz","year":"2015","unstructured":"Azouz W, Chetcuti P, Hosker HS, Saralaya D, Stephenson J, Chrystyn H. The inhalation characteristics of patients when they use different dry powder inhalers. J Aerosol Med Pulm Drug Deliv. 2015;28(1):35\u201342.","journal-title":"J Aerosol Med Pulm Drug Deliv"},{"key":"841_CR13","doi-asserted-by":"crossref","first-page":"385","DOI":"10.4104\/pcrj.2013.00097","volume":"22","author":"F Lavorini","year":"2013","unstructured":"Lavorini F, Usmani OS. Correct inhalation technique is critical in achieving good asthma control. Primary Care Respiratory Journal. 2013;22:385\u20136.","journal-title":"Primary Care Respiratory Journal"},{"issue":"2","key":"841_CR14","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1183\/20734735.014813","volume":"10","author":"M Cazzola","year":"2014","unstructured":"Cazzola M, Page C. Long-acting bronchodilators in COPD: where are we now and where are we going? Breathe. 2014;10(2):110\u201320.","journal-title":"Breathe"},{"issue":"7","key":"841_CR15","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1517\/13543784.14.7.775","volume":"14","author":"M Cazzola","year":"2005","unstructured":"Cazzola M, Matera MG, L\u00f6tvall J. Ultra long-acting \u03b22-agonists in development for asthma and chronic obstructive pulmonary disease. Expert Opin Investig Drugs. 2005;14(7):775\u201383.","journal-title":"Expert Opin Investig Drugs"},{"issue":"1","key":"841_CR16","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3109\/21556660.2013.766197","volume":"2","author":"P Colthorpe","year":"2013","unstructured":"Colthorpe P, Voshaar T, Kieckbusch T, Cuoghi E, Jauernig J. Delivery characteristics of a low-resistance dry-powder inhaler used to deliver the long-acting muscarinic antagonist glycopyrronium. Journal of Drug Assessment. 2013;2(1):11\u20136.","journal-title":"Journal of Drug Assessment"},{"issue":"11","key":"841_CR17","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1185\/03007995.2010.518916","volume":"26","author":"R Pavkov","year":"2010","unstructured":"Pavkov R, Mueller S, Fiebich K, Singh D, Stowasser F, Pignatelli G, et al. Characteristics of a capsule based dry powder inhaler for the delivery of indacaterol. Curr Med Res Opin. 2010;26(11):2527\u201333.","journal-title":"Curr Med Res Opin"},{"issue":"3","key":"841_CR18","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1007\/s11095-015-1820-1","volume":"33","author":"F Buttini","year":"2016","unstructured":"Buttini F, Pasquali I, Brambilla G, Copelli D, Dagli Alberi M, Balducci AG, et al. Multivariate analysis of effects of asthmatic patient respiratory profiles on the in vitro performance of a reservoir multidose and a capsule-based dry powder inhaler. Pharm Res. 2016;33(3):701\u201315.","journal-title":"Pharm Res"},{"issue":"1","key":"841_CR19","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.ijpharm.2013.02.034","volume":"447","author":"S Jaffari","year":"2013","unstructured":"Jaffari S, Forbes B, Collins E, Barlow DJ, Martin GP, Murnane D. Rapid characterisation of the inherent dispersibility of respirable powders using dry dispersion laser diffraction. Int J Pharm. 2013;447(1):124\u201331.","journal-title":"Int J Pharm"},{"key":"841_CR20","unstructured":"US. United States Pharmacopeia, USP 38-NF 33. 2014."},{"issue":"17","key":"841_CR21","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.2165\/11203960-000000000-00000","volume":"70","author":"MD Moen","year":"2010","unstructured":"Moen MD. Indacaterol. Drugs. 2010;70(17):2269\u201380.","journal-title":"Drugs"},{"issue":"1","key":"841_CR22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0378-5173(99)00164-7","volume":"191","author":"H Larhrib","year":"1999","unstructured":"Larhrib H, Zeng XM, Martin GP, Marriott C, Pritchard J. The use of different grades of lactose as a carrier for aerosolised salbutamol sulphate. Int J Pharm. 1999;191(1):1\u201314.","journal-title":"Int J Pharm"},{"issue":"1","key":"841_CR23","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S0378-5173(00)00347-1","volume":"200","author":"XM Zeng","year":"2000","unstructured":"Zeng XM, Martin GP, Marriott C, Pritchard J. The influence of carrier morphology on drug delivery by dry powder inhalers. Int J Pharm. 2000;200(1):93\u2013106.","journal-title":"Int J Pharm"},{"issue":"1","key":"841_CR24","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0954-6111(98)90040-3","volume":"92","author":"L Hill","year":"1998","unstructured":"Hill L, Slater A. A comparison of the performance of two modern multidose dry powder asthma inhalers. Respir Med. 1998;92(1):105\u201310.","journal-title":"Respir Med"},{"issue":"9","key":"841_CR25","first-page":"1209","volume":"50","author":"MJ Telko","year":"2005","unstructured":"Telko MJ, Hickey AJ. Dry powder inhaler formulation. Respir Care. 2005;50(9):1209\u201327.","journal-title":"Respir Care"},{"issue":"s149","key":"841_CR26","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/j.1368-504X.2005.00721.x","volume":"59","author":"A Taylor","year":"2005","unstructured":"Taylor A, Gustafsson P. Do all dry powder inhalers show the same pharmaceutical performance? Int J Clin Pract. 2005;59(s149):7\u201312.","journal-title":"Int J Clin Pract"},{"issue":"1\u20132","key":"841_CR27","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s13556-013-0003-9","volume":"3","author":"B Johal","year":"2013","unstructured":"Johal B, Howald M, Fischer M, Marshall J, Venthoye G. Fine particle profile of fluticasone propionate\/formoterol fumarate versus other combination products: the DIFFUSE study. Comb Prod Ther. 2013;3(1\u20132):39\u201351.","journal-title":"Comb Prod Ther"},{"key":"841_CR28","unstructured":"Dederichs J, Singh D, Pavkov R. Inspiratory flow profiles generated by patients with COPD through the Breezhaler\u00ae inhaler and other marketed dry powder inhalers. D37 help: advances in COPD therapeutics. Am Thoracic Soc. 2015:A5793-A."},{"issue":"1","key":"841_CR29","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/0378-5173(88)90177-9","volume":"42","author":"M Vidgren","year":"1988","unstructured":"Vidgren M, K\u00e4rkk\u00e4inen A, Karjalainen P, Paronen P, Nuutinen J. Effect of powder inhaler design on drug deposition in the respiratory tract. Int J Pharm. 1988;42(1):211\u20136.","journal-title":"Int J Pharm"},{"issue":"1","key":"841_CR30","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.ijpharm.2013.05.006","volume":"452","author":"D Heng","year":"2013","unstructured":"Heng D, Lee SH, Ng WK, Chan H-K, Kwek JW, Tan RB. Novel alternatives to reduce powder retention in the dry powder inhaler during aerosolization. Int J Pharm. 2013;452(1):194\u2013200.","journal-title":"Int J Pharm"},{"issue":"3","key":"841_CR31","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1089\/jam.2005.18.364","volume":"18","author":"M Copley","year":"2005","unstructured":"Copley M, Smurthwaite M, Roberts D, Mitchell J. Revised internal volumes of cascade impactors for those provided by Mitchell and Nagel. J Aerosol Med. 2005;18(3):364\u20136.","journal-title":"J Aerosol Med"},{"issue":"1","key":"841_CR32","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s40248-015-0033-0","volume":"10","author":"D Price","year":"2015","unstructured":"Price D, Chrystyn H. Concept review of dry powder inhalers: correct interpretation of published data. Multidisciplinary respiratory medicine. 2015;10(1):36.","journal-title":"Multidisciplinary respiratory medicine."},{"issue":"4","key":"841_CR33","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1513\/pats.200409-046TA","volume":"1","author":"J Heyder","year":"2004","unstructured":"Heyder J. Deposition of inhaled particles in the human respiratory tract and consequences for regional targeting in respiratory drug delivery. Proc Am Thorac Soc. 2004;1(4):315\u201320.","journal-title":"Proc Am Thorac Soc"},{"key":"841_CR34","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.ejpb.2015.07.016","volume":"96","author":"AH Boer de","year":"2015","unstructured":"de Boer AH, Gjaltema D, Hagedoorn P, Frijlink HW. Can \u2018extrafine\u2019 dry powder aerosols improve lung deposition? Eur J Pharm Biopharm. 2015;96:143\u201351.","journal-title":"Eur J Pharm Biopharm"},{"key":"841_CR35","doi-asserted-by":"crossref","first-page":"64","DOI":"10.33590\/emjrespir\/10313608","volume":"1","author":"N Roche","year":"2013","unstructured":"Roche N, Chrystyn H, Lavorini F, Agusti A, Virchow JC, Dekhuijzen R, et al. Effectiveness of inhaler devices in adult asthma and COPD. EMJ Respir. 2013;1:64\u201371.","journal-title":"EMJ Respir"},{"key":"841_CR36","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.ejps.2017.03.035","volume":"104","author":"M Abadelah","year":"2017","unstructured":"Abadelah M, Hazim F, Chrystyn H, Bagherisadeghi G, Rahmoune H, Larhrib H. Effect of maximum inhalation flow and inhaled volume on formoterol drug deposition in-vitro from an Easyhaler\u00ae dry powder inhaler. Eur J Pharm Sci. 2017;104:180\u20137.","journal-title":"Eur J Pharm Sci"}],"container-title":["AAPS PharmSciTech"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1208\/s12249-017-0841-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-017-0841-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-017-0841-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,24]],"date-time":"2023-08-24T11:26:33Z","timestamp":1692876393000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1208\/s12249-017-0841-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,10]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["841"],"URL":"https:\/\/doi.org\/10.1208\/s12249-017-0841-y","relation":{},"ISSN":["1530-9932"],"issn-type":[{"value":"1530-9932","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,10]]}}}